1622217-00-8 Usage
Uses
Used in Organic Synthesis:
2,4-dichloro-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is used as a reagent in organic synthesis for its ability to facilitate the formation of carbon-carbon and carbon-heteroatom bonds. Its unique structure and reactivity make it a valuable component in various chemical reactions.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 2,4-dichloro-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is used as a building block for the development of new drugs. Its versatility in forming different types of chemical bonds allows for the creation of a wide range of pharmaceutical compounds.
Used in Agrochemical Production:
Similarly, in the agrochemical industry, 2,4-dichloro-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is utilized as a key component in the synthesis of various agrochemicals, contributing to the development of effective and innovative products for agricultural applications.
Used in Materials Science:
2,4-dichloro-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine is also employed in materials science, where it serves as a building block for the creation of new materials with specific properties. Its ability to form various chemical bonds makes it suitable for the development of advanced materials with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1622217-00-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,2,2,1 and 7 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1622217-00:
(9*1)+(8*6)+(7*2)+(6*2)+(5*2)+(4*1)+(3*7)+(2*0)+(1*0)=118
118 % 10 = 8
So 1622217-00-8 is a valid CAS Registry Number.
1622217-00-8Relevant articles and documents
TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS
-
Page/Page column 414; 415, (2016/12/01)
The present invention is directed to tricyclic compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Iridium-catalyzed C-H borylation of pyridines
Sadler, Scott A.,Tajuddin, Hazmi,Mkhalid, Ibraheem A. I.,Batsanov, Andrei S.,Albesa-Jove, David,Cheung, Man Sing,Maxwell, Aoife C.,Shukla, Lena,Roberts, Bryan,Blakemore, David C.,Lin, Zhenyang,Marder, Todd B.,Steel, Patrick G.
supporting information, p. 7318 - 7327 (2014/11/07)
The iridium-catalysed C-H borylation is a valuable and attractive method for the preparation of aryl and heteroaryl boronates. However, application of this methodology for the preparation of pyridyl and related azinyl boronates can be challenged by low reactivity and propensity for rapid protodeborylation, particularly for a boronate ester ortho to the azinyl nitrogen. Competition experiments have revealed that the low reactivity is due to inhibition of the active catalyst through coordination of the azinyl nitrogen lone pair at the vacant site on the iridium. This effect can be overcome through the incorporation of a substituent at C-2. Moreover, when this is sufficiently electron-withdrawing protodeborylation is sufficiently slowed to permit isolation and purification of the C-6 boronate ester. Following functionalization, reduction of the directing C-2 substituent provides the product arising from formal ortho borylation of an unhindered pyridine ring. This journal is the Partner Organisations 2014.
